Skip to main content
QURE
NASDAQ Life Sciences

uniQure Submits BLA to FDA and MAA to UK MHRA for Huntington's Gene Therapy AMT-130

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$48.34
Mkt Cap
$3.32B
52W Low
$8.73
52W High
$71.5
52W Position info
454% above low
Off High info
32% below high
Rel. Volume info
0.4× avg
Market data snapshot near publication time

QURE has more than doubled off its 52-week low of $8.73 on light trading volume (0.4× avg).

Summary

uniQure submitted its BLA to the FDA and MAA to the UK MHRA for AMT-130, its Huntington's disease gene therapy, and requested priority review. The submissions are supported by three-year Phase I/II data showing slowed disease progression.


Key Events · Product Development and Regulatory · QURE

  • BLA Submitted to FDA

    uniQure submitted a Biologics License Application to the FDA for accelerated approval of AMT-130 for Huntington's disease, supported by three-year Phase I/II data showing slowed disease progression.

  • MAA Submitted to UK MHRA

    A Marketing Authorisation Application for AMT-130 was also submitted to the UK's MHRA, expanding the regulatory pathway into Europe.

  • Priority Review Requested

    The company requested priority review for the BLA, which if granted would shorten the FDA review cycle to six months following the 60-day filing review period.

  • Four-Year Data Presentation Planned

    uniQure intends to present a four-year data analysis from the ongoing Phase I/II studies before the end of Q3 2026.


Analysis · QURE · Life Sciences

A major regulatory milestone has been reached: uniQure has formally submitted its Biologics License Application to the FDA for accelerated approval of AMT-130 in Huntington's disease, and separately submitted a Marketing Authorisation Application to the UK MHRA. The company also requested priority review, which if granted would shorten the FDA review cycle to six months after the 60-day filing review period. This is the first gene therapy candidate for Huntington's disease to reach this stage, and the submissions are backed by three-year Phase I/II data showing slowed disease progression. The company plans to present four-year data before the end of Q3 2026. This is a major regulatory milestone that moves AMT-130 from clinical development into the approval process, with potential for accelerated approval and a near-term commercial launch.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, QURE was trading at $48.34 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.3B. The 52-week trading range was $8.73 to $71.50. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

QURE - Latest Insights

QURE
Nov 04, 2026, 7:28 AM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $22.60
Real-time Price: $20.12 info
Change: -$2.48 (-11%) info
Market Cap: $1.357B info
QURE
Nov 04, 2026, 7:10 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $22.44
Real-time Price: $20.12 info
Change: -$2.32 (-10%) info
Market Cap: $1.357B info
QURE
Nov 02, 2026, 7:05 AM EST
Source: GlobeNewswire
Importance Score:
9
Price at Filing: $27.66
Real-time Price: $20.12 info
Change: -$7.54 (-27%) info
Market Cap: $1.357B info
QURE
Sep 29, 2026, 9:26 AM EDT
Source: Dow Jones Newswires
Importance Score:
8
Price at Filing: $22.00
Real-time Price: $20.12 info
Change: -$1.88 (-9%) info
Market Cap: $1.357B info
QURE
Sep 29, 2026, 9:05 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $22.20
Real-time Price: $20.12 info
Change: -$2.08 (-9%) info
Market Cap: $1.357B info